Neurogene Total Assets from 2010 to 2026
| NGNE Stock | 20.16 0.44 2.14% |
Total Assets | First Reported 2016-09-30 | Previous Quarter 297.3 M | Current Value 287.8 M | Quarterly Volatility 69.2 M |
Check Neurogene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurogene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 M, Other Operating Expenses of 100.9 M or Research Development of 73.6 M, as well as many indicators such as Price To Sales Ratio of 410, Dividend Yield of 0.0 or PTB Ratio of 1.41. Neurogene financial statements analysis is a perfect complement when working with Neurogene Valuation or Volatility modules.
Neurogene | Total Assets | Build AI portfolio with Neurogene Stock |
Latest Neurogene's Total Assets Growth Pattern
Below is the plot of the Total Assets of Neurogene over the last few years. Total assets refers to the total amount of Neurogene assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Neurogene books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Neurogene's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurogene's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 335.73 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Neurogene Total Assets Regression Statistics
| Arithmetic Mean | 146,826,580 | |
| Geometric Mean | 81,891,529 | |
| Coefficient Of Variation | 86.42 | |
| Mean Deviation | 98,108,519 | |
| Median | 110,329,000 | |
| Standard Deviation | 126,884,741 | |
| Sample Variance | 16099.7T | |
| Range | 403.1M | |
| R-Value | 0.88 | |
| Mean Square Error | 3932.9T | |
| R-Squared | 0.77 | |
| Slope | 22,062,848 | |
| Total Sum of Squares | 257595.8T |
Neurogene Total Assets History
Other Fundumenentals of Neurogene
Neurogene Total Assets component correlations
Click cells to compare fundamentals
About Neurogene Financial Statements
Neurogene stakeholders use historical fundamental indicators, such as Neurogene's Total Assets, to determine how well the company is positioned to perform in the future. Although Neurogene investors may analyze each financial statement separately, they are all interrelated. For example, changes in Neurogene's assets and liabilities are reflected in the revenues and expenses on Neurogene's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Neurogene. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Assets | 386.1 M | 405.4 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Check out the analysis of Neurogene Correlation against competitors. For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurogene. If investors know Neurogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neurogene is measured differently than its book value, which is the value of Neurogene that is recorded on the company's balance sheet. Investors also form their own opinion of Neurogene's value that differs from its market value or its book value, called intrinsic value, which is Neurogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurogene's market value can be influenced by many factors that don't directly affect Neurogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.